Journal article
EGFR genotyping of matched urine, plasma, and tumor tissue in patients with non-small-cell lung cancer treated with rociletinib, an EGFR tyrosine kinase inhibitor
JW Goldman, C Karlovich, LV Sequist, V Melnikova, A Franovic, SM Gadgeel, KL Reckamp, DR Camidge, M Pérol, SHI Ou, SV Liu, HA Yu, JC Soria, MA Socinski, TM Mekhail, BJ Solomon, RB Natale, GA Otterson, V Papadimitrakopoulou, CJ Langer Show all
JCO Precision Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2018
DOI: 10.1200/PO.17.00116
Abstract
Purpose Liquid biopsies represent an attractive alternative to tissue biopsies, particularly rebiopsies, in determining patient eligibility for targeted therapies. Clinical utility of urine genotyping, however, has not been explored extensively. We evaluated epidermal growth factor receptor (EGFR) T790M detection in matched urine, plasma, and tissue and the clinical outcomes of patients with advanced non-small-cell lung cancer treated with rociletinib. Methods Tissue (n = 540), plasma (n = 482), and urine (n = 213) were collected from evaluable patients enrolled in TIGER-X, a phase I/II study. Genotyping was performed by therascreen EGFR testing in tissue, BEAMing in plasma, and a quantitati..
View full abstractGrants
Funding Acknowledgements
Funded by Clovis Oncology.